ISB News

Lee Hood Will Speak at ‘Xconomy Forum: Seattle Biotech Seizes the Momentum’

Dr. Lee Hood will be one of the featured speakers during the next Xconomy Forum on Seattle’s biotech revival. The event takes place on May 6 at Fred Hutchinson Cancer Research Center.

For full details, visit the event page. Promo code: Use XconFriend to get a discount at registration.

Biotech has roared back to life the past couple years, perhaps more than any other U.S. economic sector. Seattle’s biotech community is no different. Last year’s signs of revival include the ascendance of Juno Therapeutics, the burgeoning pipeline of Seattle Genetics, the kickoff of a study that could become a key part of the national precision medicine initiative, and Celgene’s decision to build an R&D center in town.

How should Seattle biotech seize the momentum? Join us at the Fred Hutchinson Cancer Research Center to take part in the discussion.

Confirmed Speakers:

  • Gary Gilliland, President and Director, Fred Hutchinson Cancer Research Center
  • Randy Schatzman, CEO, Alder Biopharmaceuticals
  • Lee Hood, President, The Institute for Systems Biology
  • Chad Robins, President and CEO, Adaptive Biotechnologies
  • Bob Nelsen, Co-founder and Managing Director, ARCH Venture Partners
  • Heather Franklin, CEO, Blaze Bioscience
  • Hans Bishop, CEO, Juno Therapeutics
  • Charlotte Hubbert, Program Investment Officer, The Bill & Melinda Gates Foundation
  • Vikram Jandhyala, Vice President for Innovation, UW Center for Commercialization
  • Matt McIlwain, Managing Director, Madrona Venture Group
  • Mike Gallatin, Senior Advisor, Frazier Healthcare

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.